

High Prevalence of 16S rRNA methylase genes Among Carbapenem-resistant Hypervirulent *Klebsiella pneumoniae* Isolates in China

Wenjian Liao (✉ 897854867@qq.com)

ORCID iD: <https://orcid.org/0000-0001-8086-3911>

Dan Li

First Affiliated Hospital of Nanchang University

Dan Dan Wei

First Affiliated Hospital of Nanchang University

Fang-lin Du

First Affiliated Hospital of Nanchang University

Dan Long

First Affiliated Hospital of Nanchang University

Wei Zhang

First Affiliated Hospital of Nanchang University

Yang Liu

First Affiliated Hospital of Nanchang University

Research article

Keywords: plasmid-mediated 16S rRNA methylase, carbapenem-resistant, *K.pneumoniae*, hypervirulence

Posted Date: September 23rd, 2019

DOI: <https://doi.org/10.21203/rs.2.14808/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background : the existence of 16S rRNA methylase genes would increase treatment difficulty of patients infected with CR-hvKP strains, this study was aimed to testify the prevalence of the 16S rRNA methylase genes in the CR-hvKP strains in China. **Methods :** Thirty-nine carbapenem-resistant hypervirulent *Klebsiella pneumoniae* (CR-hvKP) isolates collected from a Chinese hospital during the whole year of 2018 were evaluated to characterize the prevalence of 16S rRNA methylase genes. **Results :** In total 66.7% (26/39) of the CR-hvKP isolates were found to carry 16S rRNA methylase genes, and the most frequently detected gene was *armA* (11.42.3%), followed by *rmtB* (8.30.8%), and 7 CR-hvKP strains were found to carry both *armA* and *rmtB* (26.9%). All the clinical isolates were found to carry at least one carbapenemase gene, with *KPC-2* (79.5%,31/39), *NDM-1* (10.3%,4/39), and cocarrying *KPC-2* and *NDM-1* (10.3%,4/39). A total of 89.7% (35/39) isolates carried ESBL genes, including 61.5% (24/39) *blaSHV-1*, 71.8% (28/39) *blaTEM-1* and 89.7% (35/39) *blaCTX-M-1*. All except four isolates (89.7%,35/39) harbored PMQR genes, with *qnrS* (82.1%,32/39), *aac(6)-Ib-cr* (79.5%,31/39), *qnrB* (2.6%,1/39). All the 16S rRNA methylase genes-positive CR-hvKP strains were firstly found to cocarry carbapenemase genes, ESBL genes and PMQR genes simultaneously. The most prevalent virulence genes were *rmpA2* and *entB* (100%, 39/39), followed by *silS* (97.4%, 38/39), *ybtS* (94.9%, 37/39), *iutA* (92.3%, 36/39), *kpn* (92.3%, 36/39), *rmpA* (87.2%, 34/39), *terW* (84.6%, 33/39), *aerobactin* (23.1%, 9/39), *repA* (17.9%, 7/39), *magA* (10.3%, 4/39), *kfuB C* (10.3%, 4/39), *wca G* (10.3%, 4/39), *allS* (10.3%, 4/39). Multilocus sequence typing (MLST) analysis assigned the 39 CR-hvKP isolates into 4 sequence types (STs), with ST11 encompassing 79.5% of the strains. Pulsed field gel electrophoresis (PFGE) typing showed that strains closely related by MLST clustered in major PFGE clusters, of which cluster A accounts for 31 ST11 isolates. The analysis of the transconjugants showed a high-level aminoglycoside resistance and a popular cotransfer of *bla KPC-2* with the 16S rRNA methylase genes. **Conclusions :** 16S rRNA methylase genes are highly prevalent in CR-hvKP clinical isolates especially for ST11, it is therefore critical to continuously monitor the 16S rRNA methylase-producing CR-hvKP epidemiology and minimize potential risks from aminoglycoside-resistant CR-hvKP.

Background

Klebsiella pneumoniae is one of the common pathogens of nosocomial infections including bloodstream infections, pneumonia, urinary tract infections and liver abscesses[1]. Recently carbapenem-resistant hypervirulent *klebsiella pneumoniae* (CR-hvKP) infections have been reported widely in China[2-4]. Due to acquisition of the carbapenem-resistance plasmid by the hvKP strains or the acquisition of the virulence plasmid by the CRKP strains, CR-hvKP strains simultaneously exhibit the features of hyper-resistance, hypervirulence, and high transmissibility so that they should be regarded as a real superbug which need to raise enough concerns[5].

In spite of ototoxicity and nephrotoxicity, aminoglycosides (AGs) are few optional semisynthetic antimicrobial agents exhibiting high-susceptibility and excellent post-antibiotic effect against CRKP strains[6,7]. The biological mechanisms of resistance to aminoglycosides include decreased permeability, increased efflux, enzymatic modification, and modifications of the 30S ribosomal subunit that interferes with binding of the aminoglycosides[8]. Over the past few decades some studies have found alarmingly high rate of 16S rRNA methylase genes among CRKP strains[9,10], it precludes the use of key aminoglycosides (gentamicin, tobramycin, and amikacin) even when carbapenems have already been excluded from the treatment option. Obvious the existence of 16S rRNA methylase genes would increase treatment difficulty of patients infected with CR-hvKP strains. Thus, this study was aimed to testify the prevalence of the 16S rRNA methylase genes in the CR-hvKP strains in China.

Methods

Bacterial strains and antimicrobial susceptibilities

A total of 513 nonduplicate *Klebsiella pneumoniae* clinical isolates were collected from the First Affiliated Hospital of Nanchang University in the southeastern region of China from January to December 2018. Among these, 39 CR-hvKP clinical isolates were selected from clinical specimens, including 21 blood, 14 sputum, 1 pus, 1 urine, and 2 other specimen sources, respectively. According to the latest definition of hvKP[11], we selected the CRKP strains carrying the pLVPK-like virulence plasmid as CR-hvKP strains in this study. *K. pneumoniae* isolates were identified by an automated Vitek II system (bioMérieux, Balmes-les-Grottes, France) and were further verified with 16S rRNA gene sequencing. Antibiotic susceptibilities were determined by the disk diffusion method on Mueller-Hinton agar according to the Clinical and Laboratory Standards Institute (CLSI) guidelines[12]. *Escherichia coli* ATCC 25922 and *K. pneumoniae* ATCC 700603 were used as the quality control. *E. coli* J53 was used in the conjugation experiments.

PCR detection of resistance genes and virulence-associated genes

The DNA was extracted with the boiling method in sterile distilled water for ten minutes. Single PCR was used to analyze genes PMQR (*qnrA*, *qnrB*, *qnrS*, *qepA*, and *aac(6)-Ib-cr*)[13], ESBLs (*CTX-M*, *SHV*, *TEM*)[14], and carbapenemase genes (*KPC*, *IMP*, *VIM*, *NDM*, *OXA-48*)[15] with specific primers for each one, as previously reported. Additionally, all isolates were screened for the presence of the 16S rRNA methylase genes, including *armA*, *rmtA*, *rmtB*, *npmA*, *rmtC*, *rmtD*, by PCR and DNA sequencing[16]. Capsular serotyping gene *K1*, *K2* and fourteen virulence genes, including *aerobactin*, *rmpA2*, *terW*, *kfuBC*, *rmpA*, *allS*, *silS*, *iutA*, *ybtS*, *wcaG*, *kpn*, *entB*, *magA*, and *repA*, were identified using polymerase chain reaction (PCR) amplification as described in previous papers[17,18]. All the PCR products were purified and sequenced and the sequences were compared with the reference deposited in the GenBank nucleotide database.

Conjugation experiments

Luria–Bertani (LB) mating experiments were performed using sodium azide-resistant *E. coli* J53 as the recipient to determine whether the 16S rRNA methylase genes or the carbapenemase genes are transferable. Transconjugants were selected on LB plates containing sodium azide (100 mg/L) plus gentamicin (30 mg/L) or imipenem (4 mg/L), and finally confirmed by PCR and pulsed field gel electrophoresis (PFGE)[19]. We also performed PCR to confirm whether the transconjugants also contained the other antibiotic-resistance genes that were found in the donor strains.

PFGE and MLST

All the CR-hvKP isolates were subjected to PFGE after digestion with XbaI, as previously described²⁰. The cluster cutoff line at 80% similarity was used to analyze genetic relatedness. Seven conserved house keeping genes (*gapA*, *infB*, *mdh*, *pgi*, *phoE*, *rpoB*, *tonB*) were used to perform MLST (<http://www.pasteur.fr/recherche/genopole/PF8/mlst/Klebsiellapneumoniae.html>).

Results

The clinical characteristics and the association of antibiotic susceptibilities with 16S rRNA methylase genes in CR-hvKP isolates

Overall, 39 patients had proven or suspected acquisition of CP-hvKP, more than half of all patients (64.1%) had the carbapenems application empirically, but only 7 patients (17.9%) had the aminoglycosides application. On the basis of the presence of 16S rRNA methylase genes in these CR-hvKP strains, all CR-hvKP strains were divided into two groups (16S rRNA methylase genes-positive strains and 16S rRNA methylase genes-negative strains). PCR analysis of 16S rRNA methylase genes revealed 26 (66.7%) CR-hvKP isolates had 16S rRNA methylase genes and 13 (33.3%) CR-hvKP isolates had no any 16S rRNA methylase genes. There was no significant difference in eight antimicrobial susceptibilities except aminoglycosides susceptibilities between two groups. Twenty-six 16S rRNA methylase genes-positive strains were all resistant to Amikacin, gentamicin and tobramycin. Thirteen 16S rRNA methylase genes-negative strains were all susceptible to amikacin and gentamicin, but only three 16S rRNA methylase genes-negative strains were still susceptible to tobramycin. Almost all the CR-hvKP strains were resistant to carbapenems, beta lactam antibiotics and quinolones, only one 16S rRNA methylase genes-negative strain was susceptible to levofloxacin. Fortunately there were four 16S rRNA methylase genes-negative strains and eight 16S rRNA methylase genes-positive strains susceptible to co-trimoxazole. All the CR-hvKP strains exhibited the hypervirulence that all the patients had high ICU admission rate (51.2%) and high mortality (58.9%) in 30 days in spite of 16S rRNA methylase genes (Table 1).

Prevalence of 16S rRNA methylase genes and other antimicrobial resistance genes among CR-hvKP clinical strains

As shown in Table 2, 66.7% (26/39) of the CR-hvKP isolates were found to carry at least one 16S rRNA methylase gene, with *armA*, *rmtB* being detected alone or in combination in 11, 8, and 7 strains, respectively. However, *rmtA*, *npmA*, *rmtC* and *rmtD* were not detected in these strains. All the clinical isolates were found to carry at least one carbapenemase gene, with *KPC-2* (79.5%, 31/39), *NDM-1* (10.3%, 4/39), cocarrying *KPC-2* and *NDM-1* (10.3%, 4/39). However, *IMP*, *VIM*, *OXA-48* were not detected in these strains. A total of 89.7% (35/39) isolates carried ESBL genes, including 61.5% (24/39) *blaSHV-1*, 71.8% (28/39) *blaTEM-1* and 89.7% (35/39) *blaCTX-M-14*. All except four isolates (89.7%, 35/39) harbored PMQR genes, with *qnrS* (82.1%, 32/39), *aac(6)-Ib-cr* (79.5%, 31/39), *qnrB* (2.6%, 1/39). All the 16S rRNA methylase genes-positive CR-hvKP strains were firstly found to cocarry carbapenemase genes, ESBL genes and PMQR genes simultaneously (Table 2).

Capsular serotyping K1/K2 and Virulence genes in CR-hvKP clinical strains

Capsular serotyping showed that of 39 CR-hvKP strains, both four isolates were identified as capsular genotypes K1 and K2. The 14 investigated virulence genes were detected in the K. pneumoniae isolates and are shown in Table 2. Various virulence-associated genes are responsible for determining the pathogenicity of the 39 K. pneumoniae isolates tested, including *magA* (10.3%, 4/39), *rmpA* (87.2%, 34/39), *terW* (84.6%, 33/39), *silS* (97.4%, 38/39), *iutA* (92.3%, 36/39), *rmpA2* (100%, 39/39), *kfuBC* (10.3%, 4/39), *wcaG* (10.3%, 4/39), *allS* (10.3%, 4/39), *kpn* (92.3%, 36/39), *entB* (100%, 39/39), *ybtS* (94.9%, 37/39), *repA* (17.9%, 7/39), and *aerobactin* (23.1%, 9/39). The positive rates of *magA*, *kfuBC*, *wcaG*, *allS*, and *aerobactin* among K1/K2 isolates were significantly higher than non-K1/K2 isolates ($p < 0.05$).

Molecular characteristics

The PFGE-based fingerprints of the CR-hvKP isolates displayed three different clusters (named A-C) using a similarity cutoff value of 80% (Fig. 1), including cluster A (31/39, 79.5%), cluster B (4/39, 10.3%) and cluster C (4/39, 10.3%). The MLST analysis distinguished a total of four different STs. The most prevalent ST in CR-hvKP isolates was ST11 (31/39, 79.5%), followed by ST23 (4/39, 10.3%), ST65 (2/39, 5.1%), and ST86 (2/39, 5.1%). Notably, MLST and PFGE yielded similar results, with 31 cluster A isolates belonging to ST11, 4 cluster B isolates belonging to ST23, and both two cluster C isolates belonging to ST65 and ST86, respectively. The PFGE-based fingerprints of ST11 *KPC-2* hvKP from different wards were almost the same and the 16S rRNA methylase genes positive rate in this kind of CR-hvKP strains was quite high (67.7%). Our data revealed that ST11 *KPC-2* hvKP strains were highly transmissible clonally and were extremely easy to cocarry the 16S rRNA methylase genes.

Conjugation experiments

In conjugation experiments, twenty-six 16S rRNA methylase genes positive strains were used as donors. The transconjugation were successful in 17 (65.4%) CR-hvKP strains, including 9 *armA*-positive strains, 5 *rmtB*-positive strains, 3 *armA-rmtB*-positive strains. 16S rRNA methylase genes were found in 12 transconjugants by PCR and only *rmtB* was found in 3 *armA-rmtB*-positive transconjugants, indicating that only *rmtB* was present on the

transferable plasmid in these *armA-rmtB*-positive strains. Additionally, the analysis of the transconjugants revealed a common cotransmission of *blaKPC-2* with the 16S rRNA methylase genes that both 16S rRNA methylase genes and *KPC-2* were positive in 9 transconjugants.

Discussion

Over the past few decades, hvKP has globally emerged, causing invasive infections since the first clinical hvKP report in 1986[21]. Although initial isolates of hvKp were antimicrobial sensitive, clonal complexes of hypervirulent (hvKP) and multidrug-resistant (MDR) strains are non-overlapping[22]. In this study we collected 39 CR-hvKP strains, including 31 ST11 CRKP carrying the pLVKp like plasmid, 4 ST23, 2 ST65 and 2 ST86 hvKP carrying the carbapenemase plasmid. It was consistent with the evolution hypothesis of MDR-hvKP occurring by two mechanisms[21]. The first and more frequent was via XDR cKp acquiring a modified hvKp virulence plasmid, and the converse was via hvKp strains gaining antimicrobial resistance genes by acquisition of resistance plasmids or by the insertion of resistance elements into hvKp's virulence plasmid[5,21]. To date, though such CR-hvKP strains have been described only in China; the prospect of CR-hvKp undergoing wider dissemination is concerning.

Because of the expensive cost, the application of tigecycline and polymyxin in clinical treatment were severely limited. Considering that CRKP isolates were generally susceptible to aminoglycosides, these drugs were widely used for treating CRKP infections[6] in spite of ototoxicity and nephrotoxicity. However, increased manifestations of antimicrobial resistance mediated by plasmids, especially 16S rRNA methylase, and carbapenemase in MDR *K. pneumoniae*, had been observed in China[23]. In this study the 16S rRNA methylase genes were highly prevalent in CR-hvKP isolates. The most frequently detected 16S rRNA methylase genes was *armA*, followed by *rmtB* and both two in all isolates. As described in a previous study[24], 16S rRNA methylase genes conferred high-level aminoglycoside resistance including amikacin, gentamicin and tobramycin in CR-hvKP strains this study. Previous studies had identified an increasing association between carbapenemase production and aminoglycoside resistance[9,23,25]. Carbapenemase encoding genes could be cotransferred with 16S rRNA methylase genes on the same mobile genetic elements[23]. Furthermore, increasing numbers of hvKP isolates with carbapenemase have been reported from different parts of China[3,26,27]. In the present study, a high percentage (52.9%, 9/17) of 16S rRNA methylase gene *armA* or *rmtB* was cotransferred with carbapenemase encoding gene *KPC-2* among these CR-hvKP. Even more disturbing was that *KPC-2*-type carbapenemase was common genotype in China. Interestingly we firstly found that carbapenemase gene *NDM-1* and 16S rRNA methylase gene *armA* both were simultaneously present in one CR-hvKP strain this study, but whether these two drug resistance genes existed in the same plasmid needed further study by Southern-blot.

As previous studies reported several gene clusters were associated with virulence in hvKP K1/K2 serotype strains[28,29], virulence genes including *aerobact*, *repA*, *kfuBC* and *wcaG* were highly clustered in the K1/K2 16S rRNA methylase genes-positive CR-hvKP strains compared to non-K1/K2 16S rRNA methylase genes-positive strains. Our data showed that ST11 was the most prevalent among 16S rRNA methylase genes-positive CR-hvKP isolates. Among 21 ST11 isolates, the first and second isolates were emerged in January 2018 in our hospital, whereas 14 isolates were identified during the period from April to July 2017. In August and September, four ST11 isolates were identified, and the last isolate was found in December. Our data indicated that there was an outbreak of ST11 16S rRNA methylase genes-positive CR-hvKP in our hospital in 2018. Control measures should be implemented to prevent further dissemination of such organisms in the hospital setting, because the ST11 carbapenem-resistant hypervirulent *K. pneumoniae* strains are simultaneously hypervirulent, multidrug resistant, and highly transmissible[4]. In addition, ST23, ST65 and ST86 were also found to be associated with 16S rRNA methylase genes-positive CR-hvKP.

Several potential limitations and caveats of this study are noteworthy, including its retrospective nature and a relatively small study population. In this study, 39 isolates used in the analysis were unable to clearly elucidate the 16S rRNA methylase genes-positive CR-hvKP epidemiology. Therefore, there may be selection bias, which limits the general application of study results to other areas.

Conclusions

In conclusion, 16S rRNA methylase genes are highly prevalent in CR-hvKP clinical isolates in our hospital, and 16S rRNA methylase genes-positive CR-hvKP strains especially for ST11 will be difficult to eliminate and control because of both horizontal transfer and clonal spread. Furthermore, the 16S rRNA methylase genes could be cotransferred with *blaKPC*, suggesting that CR-hvKP could acquire transferable resistance elements as independent events from an external source, of which we should keep alert

Abbreviations

CR-hvKP: carbapenem-resistant hypervirulent *Klebsiella pneumoniae*

CRKP: carbapenem-resistant *Klebsiella pneumoniae* hvKP: hypervirulent *Klebsiella pneumoniae*

PMQR: plasmid-mediated quinolone resistance MLST: multilocus sequence typing

PFGE: Pulsed-field gel electrophoresis

Declarations

Ethics approval and consent to participate

The study has been evaluated by the Ethics Committee of the First Affiliated Hospital of Nanchang University. Patients involved in the study were anonymized, no informed consent was acquired because of the retrospective study.

Consent for publication

Not applicable

Availability of data and material

The data that support the findings of this study are available from the corresponding author upon reasonable request

Competing interests

The author reports no conflicts of interest in this work.

Funding

Financial support was provided by the National Natural Science Foundation of China (81860368).

Author contributions

FLD and DL performed the laboratory measurements. YL and WJL made substantial contributions to conception and design. WZ and YL revised the manuscript critically for important intellectual content. DL and DDW participated in experimental design and data analysis. WJL drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgments

Not applicable.

References

1. Paczosa MK, Mecsas J: Klebsiella pneumoniae: Going on the Offense with a Strong Defense. *Microbiol Mol Biol Rev* 2016, 80:629-661.
2. Dong N, Liu L, Zhang R, Chen K, Xie M, EWC C, Chen S: An IncR Plasmid Harbored by a Hypervirulent Carbapenem-Resistant Klebsiella pneumoniae Strain Possesses Five Tandem Repeats of the blaKPC-2::NTEKPC-Id Fragment. *Antimicrob Agents Chemother* 2019, 63:
3. Liu Y, Long D, Xiang TX, et al. Whole genome assembly and functional portrait of hypervirulent extensively drug-resistant NDM-1 and KPC-2 co-producing Klebsiella pneumoniae of capsular serotype K2 and ST86. *J Antimicrob Chemother.* 2019 .
4. Gu D, Dong N, Zheng Z, et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. *Lancet Infect Dis.* 2018. 18(1): 37-46.
5. Wyres KL, Wick RR, Judd LM, et al. Distinct evolutionary dynamics of horizontal gene transfer in drug resistant and virulent clones of Klebsiella pneumoniae. *PLoS Genet.* 2019. 15(4): e1008114.
6. Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. *Antimicrob Agents Chemother.* 2011. 55(12): 5893-9.
7. Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. *Expert Rev Anti Infect Ther.* 2013. 11(2): 159-77.
8. Doi Y, Wachino JI, Arakawa Y. Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases. *Infect Dis Clin North Am.* 2016. 30(2): 523-537.
9. Tada T, Tsuchiya M, Shimada K, et al. Dissemination of Carbapenem-resistant Klebsiella pneumoniae clinical isolates with various combinations of Carbapenemases (KPC-2, NDM-1, NDM-4, and OXA-48) and 16S rRNA Methylases (RmtB and RmtC) in Vietnam. *BMC Infect Dis.* 2017. 17(1): 467.
10. Tada T, Miyoshi-Akiyama T, Dahal RK, et al. Dissemination of multidrug-resistant Klebsiella pneumoniae clinical isolates with various combinations of carbapenemases (NDM-1 and OXA-72) and 16S rRNA methylases (ArmA, RmtC and RmtF) in Nepal. *Int J Antimicrob Agents.* 2013. 42(4): 372-4.
11. Xu M, Fu Y, Fang Y, et al. High prevalence of KPC-2-producing hypervirulent Klebsiella pneumoniae causing meningitis in Eastern China. *Infect Drug Resist.* 2019. 12: 641-653.
12. Humphries RM, Ambler J, Mitchell SL, et al. CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests. *J Clin Microbiol.* 2018. 56(4).
13. Li P, Liu D, Zhang X, et al. Characterization of Plasmid-Mediated Quinolone Resistance in Gram-Negative Bacterial Strains from Animals and Humans in China. *Microb Drug Resist.* 2019 .
14. Kazemian H, Heidari H, Ghanavati R, et al. Phenotypic and Genotypic characterization of ESBLs, AmpC and Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli Isolates. *Med Princ Pract.* 2019 .
15. Liu Y, Wan LG, Deng Q, Cao XW, Yu Y, Xu QF. First description of NDM-1-, KPC-2-, VIM-2- and IMP-4-producing Klebsiella pneumoniae strains in a single Chinese teaching hospital. *Epidemiol Infect.* 2015. 143(2): 376-84.

16. Yeganeh SF, Mohammadzadeh-Asl Y, Ghotaslou R. High-Level Resistance to Aminoglycosides due to 16S rRNA Methylation in Enterobacteriaceae Isolates. *Microb Drug Resist.* 2019 .
17. Turton JF, Perry C, Elgohari S, Hampton CV. PCR characterization and typing of *Klebsiella pneumoniae* using capsular type-specific, variable number tandem repeat and virulence gene targets. *J Med Microbiol.* 2010. 59(Pt 5): 541-7.
18. Candan ED, Aksöz N. *Klebsiella pneumoniae*: characteristics of carbapenem resistance and virulence factors. *Acta Biochim Pol.* 2015. 62(4): 867-74.
19. Liu Y, Du FL, Xiang TX, et al. High Prevalence of Plasmid-Mediated Quinolone Resistance Determinants Among Serotype K1 Hypervirulent *Klebsiella pneumoniae* Isolates in China. *Microb Drug Resist.* 2019. 25(5): 681-689.
20. Wang Z, Li M, Shen X, et al. Outbreak of bla_{NDM-5}-Harboring *Klebsiella pneumoniae* ST290 in a Tertiary Hospital in China. *Microb Drug Resist.* 2019 .
21. Russo TA, Marr CM. Hypervirulent *Klebsiella pneumoniae*. *Clin Microbiol Rev.* 2019. 32(3).
22. Hennequin C, Robin F. Correlation between antimicrobial resistance and virulence in *Klebsiella pneumoniae*. *Eur J Clin Microbiol Infect Dis.* 2016. 35(3): 333-41.
23. Wei DD, Wan LG, Yu Y, et al. Characterization of extended-spectrum beta-lactamase, carbapenemase, and plasmid quinolone determinants in *Klebsiella pneumoniae* isolates carrying distinct types of 16S rRNA methylase genes, and their association with mobile genetic elements. *Microb Drug Resist.* 2015. 21(2): 186-93.
24. Yan JJ, Wu JJ, Ko WC, et al. Plasmid-mediated 16S rRNA methylases conferring high-level aminoglycoside resistance in *Escherichia coli* and *Klebsiella pneumoniae* isolates from two Taiwanese hospitals. *J Antimicrob Chemother.* 2004. 54(6): 1007-12.
25. Taylor E, Sriskandan S, Woodford N, Hopkins KL. High prevalence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacteriaceae in the UK and Ireland. *Int J Antimicrob Agents.* 2018. 52(2): 278-282.
26. Yao B, Xiao X, Wang F, Zhou L, Zhang X, Zhang J. Clinical and molecular characteristics of multi-clone carbapenem-resistant hypervirulent (hypermucoviscous) *Klebsiella pneumoniae* isolates in a tertiary hospital in Beijing, China. *Int J Infect Dis.* 2015. 37: 107-12.
27. Liu BT, Su WQ. Whole genome sequencing of NDM-1-producing serotype K1 ST23 hypervirulent *Klebsiella pneumoniae* in China. *J Med Microbiol.* 2019. 68(6): 866-873.
28. Turton JF, Payne Z, Coward A, et al. Virulence genes in isolates of *Klebsiella pneumoniae* from the UK during 2016, including among carbapenemase gene-positive hypervirulent K1-ST23 and 'non-hypervirulent' types ST147, ST15 and ST383. *J Med Microbiol.* 2018. 67(1): 118-128.
29. Yu WL, Ko WC, Cheng KC, Lee CC, Lai CC, Chuang YC. Comparison of prevalence of virulence factors for *Klebsiella pneumoniae* liver abscesses between isolates with capsular K1/K2 and non-K1/K2 serotypes. *Diagn Microbiol Infect Dis.* 2008. 62(1): 1-6.

Tables

Table 1|The clinical characteristics and the association of antibiotic susceptibilities with 16S rRNA methylase genes in CR-hvKP isolates

	16S rRNA methylase genes		P-value
	Positive(n=26)	Negative(n=13)	
Clinical characteristics			
Age(year>65)	7	5	0.713
Sex(male)	20	11	0.888
Brain injury	16	10	0.548
Diabetes	6	1	0.388
Hypertension	10	2	0.270
Pulmonary infection	12	5	0.648
Carbapenems application	17	8	0.813
Aminoglycosides application	5	2	0.571
Quinolones application	4	1	0.468
Any ICU admission	13	7	0.821
Mortality in 30 days	16	7	0.645
Antimicrobial susceptibility			
Levofloxacin	0	1	NA
Tobramycin	0	3	0.037
Gentamincin	0	11	<0.001
Piperacillin tazobactam	0	0	NA
Trimethoprim	8	4	0.637
AmiKacin	0	13	<0.001
Ceftazidime	0	0	NA
Aztreonam	0	0	NA
Imipenem/Meropenem	0	0	NA
Cefazolin	0	0	NA
Ceftriaxone	0	0	NA

Statistically significant correlations ($p < 0.05$) are shown in bold font.

Table 2. Main Features of all CR-hvKP isolates and the drug resistance genes results of 16SrRNA methylase gene-positive CR-KP transconjugants

Isolates	Specimen	Virulence genes	16SrRNA methylase gene	carbapenemase genes	Other resistant genes
Kp1	Sputum	<i>rmpA,terW,silS,iutA,rmpA2,kpn,entB,ytbs,kpn,entB,ytbs</i>	-	<i>KPC-2</i>	<i>SHV-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
Kp2	Urine	<i>rmpA,terW,silS,iutA,rmpA2,kpn,entB,ytbs,kpn,entB,ytbs</i>	-	<i>KPC-2</i>	<i>CTX-M-14,qnrS,acc(6')-Ib-cr</i>
Kp3	Blood	<i>rmpA,terW,silS,iutA,rmpA2,kpn,entB,ytbs,aerobact</i>	-	<i>KPC-2</i>	<i>TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
Kp4	Blood	<i>rmpA,terW,silS,iutA,rmpA2,kpn,entB,ytbs</i>	-	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
Kp5	Blood	<i>rmpA,terW,silS,iutA,rmpA2,kpn,entB,ytbs</i>	-	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
Kp6	Blood	<i>rmpA,terW,silS,iutA,rmpA2,kpn,entB,ytbs</i>	-	<i>KPC-2</i>	<i>TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
Kp7	Blood	<i>rmpA,terW,silS,iutA,rmpA2,kpn,entB,ytbs</i>	-	<i>KPC-2</i>	<i>TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
Kp8	Blood	<i>rmpA,terW,silS,iutA,rmpA2,kpn,entB,ytbs</i>	-	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
Kp9	Blood	<i>rmpA,terW,silS,iutA,rmpA2,kpn,entB,ytbs</i>	-	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
Kp10	Blood	<i>rmpA,terW,silS,iutA,rmpA2,kpn,entB,ytbs</i>	-	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
Kp11	Sputum	<i>rmpA,terW,silS,iutA,rmpA2,kpn,entB,ytbs</i>	<i>armA</i>	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
T-KP11	-	-	<i>armA</i>	<i>KPC-2</i>	<i>TEM-1</i>
Kp12	Sputum	<i>rmpA,,silS,iutA,rmpA2,kpn,entB,ytbs</i>	<i>rmtB</i>	<i>NDM-1//KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS</i>
T-KP12	-	-	-	-	-
Kp13	Sputum	<i>rmpA,terW,silS,iutA,rmpA2,kpn,entB,ytbs</i>	<i>rmtB</i>	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,acc(6')-Ib-cr</i>
T-KP13	-	-	<i>rmtB</i>	<i>KPC-2</i>	<i>TEM-1,acc(6')-Ib-cr</i>
Kp14	Sputum	<i>rmpA,terW,silS,iutA,rmpA2,kpn,entB,ytbs</i>	<i>armA//rmtB</i>	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
T-KP14	-	-	<i>rmtB</i>	<i>KPC-2</i>	<i>TEM-1,qnrS,</i>
Kp15	Sputum	<i>rmpA,,silS,iutA,rmpA2,kpn,entB,ytbs,repA</i>	<i>armA</i>	<i>NDM-1//KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
T-KP15	-	-	<i>armA</i>	-	<i>TEM-1,acc(6')-Ib-cr</i>
Kp16	Balf	<i>rmpA,,silS,iutA,rmpA2,kpn,entB,ytbs</i>	<i>armA</i>	<i>NDM-1//KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
T-KP16	-	-	<i>armA</i>	-	-

Continued

TEM-1,acc(6')-Ib-cr

Table 2. Continued

Isolates					
Kp17	Sputum	<i>rmpA,terW,silS,iutA,rmpA2 kpn,entB,ytbs</i>	<i>armA</i>	<i>KPC-2</i>	<i>SHV-1,CTX-M-14,qnrS acc(6')-Ib-cr</i>
T-KP17	-	-	-	-	-
Kp18	Blood	<i>rmpA,terW,silS,iutA,rmpA2 kpn,entB,ytbs</i>	<i>armA</i>	<i>KPC-2</i>	<i>TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
T-KP18	-	-	-	<i>KPC-2</i>	<i>TEM-1,acc(6')-Ib-cr</i>
Kp19	Blood	<i>rmpA,terW,silS,iutA,rmpA2 kpn,entB,ytbs,repA,,aerobact</i>	<i>armA</i>	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS, acc(6')-Ib-cr</i>
T-KP19	-	-	<i>armA</i>	-	<i>CTX-M-14</i>
Kp20	Sputum	<i>terW,,silS,iutA,rmpA2,kpn, entB,ytbs</i>	<i>armA</i>	<i>KPC-2</i>	<i>TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
T-KP20	-	-	-	<i>KPC-2</i>	<i>TEM-1,acc(6')-Ib-cr</i>
Kp21	Sputum	<i>terW,,silS,iutA,rmpA2 kpn,entB,ytbs,aerobact</i>	<i>armA</i>	<i>KPC-2</i>	<i>TEM-1,CTX-M-14,qnrB,qnrS, acc(6')-Ib-cr</i>
T-KP21	-	-	<i>armA</i>	<i>KPC-2</i>	<i>CTX-M-14</i>
Kp22	Blood	<i>rmpA,,silS,iutA,rmpA2,kpn, entB,ytbs</i>	<i>armA</i>	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS, acc(6')-Ib-cr</i>
T-KP22	-	-	-	-	-
Kp23	Blood	<i>rmpA,,silS,iutA,rmpA2,kpn, entB,ytbs</i>	<i>rmtB</i>	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS, acc(6')-Ib-cr</i>
T-KP23	-	-	<i>rmtB</i>	<i>KPC-2</i>	<i>TEM-1,qnrS</i>
Kp24	Blood	<i>rmpA,,silS,iutA,rmpA2,kpn, entB,ytbs</i>	<i>rmtB</i>	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS</i>
T-KP24	-	-	<i>rmtB</i>	<i>KPC-2</i>	<i>TEM-1,qnrS</i>
Kp25	Blood	<i>rmpA,terW,silS,iutA,rmpA2 kpn,entB,ytbs</i>	<i>rmtB</i>	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS, acc(6')-Ib-cr</i>
T-KP25	-	-	-	<i>KPC-2</i>	<i>TEM-1,acc(6')-Ib-cr</i>
Kp26	Blood	<i>rmpA,terW,silS,iutA,rmpA2 kpn,entB,ytbs</i>	<i>rmtB</i>	<i>KPC-2</i>	<i>TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
T-KP26	-	-	<i>rmtB</i>	<i>KPC-2</i>	<i>TEM-1,qnrS</i>
Kp27	Blood	<i>rmpA,terW,silS,iutA,rmpA2 kpn,entB,ytbs</i>	<i>armA/rmtB</i>	<i>KPC-2</i>	<i>TEM-1,CTX-M-14,qnrS,acc(6')-Ib-cr</i>
T-KP27	-	-	-	-	-

Continued

Isolates	Specimen	Virulence genes	16SrRNA methylase gene	carbapenemase genes	Other resistant genes
Kp28	Blood	<i>rmpA,terW,silS,iutA,rmpA2 kpn,entB,ytbs</i>	<i>armA/rmtB</i>	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS, acc(6')-Ib-cr</i>
T-KP28	-	-	-	-	-
Kp29	Sputum	<i>terW,silS,rmpA2 kpn,entB,ytbs,repA</i>	<i>armA/rmtB</i>	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14,qnrS, acc(6')-Ib-cr</i>
T-KP29	-	-	-	-	-
Kp30	Sputum	<i>terW,silS,rmpA2 kpn,entB,ytbs,repA</i>	<i>armA/rmtB</i>	<i>KPC-2</i>	<i>SHV-1,TEM-1,CTX-M-14</i>
T-KP30	-	-	<i>rmtB</i>	<i>KPC-2</i>	<i>TEM-1,acc(6')-Ib-cr</i>

Kp31	Sputum	<i>rmpA, terW, silS, rmpA2, kpn, entB, ytbs, repA</i>	<i>armA</i>	<i>KPC-2</i>	<i>SHV-1, TEM-1, CTX-M-14, qnrB, qnrS, acc(6')-Ib-cr</i>
T-KP31	-	-	-	<i>KPC-2</i>	<i>CTX-M-14, qnrS,</i>
Kp32	Blood	<i>magA, rmpA, terW, silS, iutA, rmpA2, kfuBC, wcaG, allS, entB, ytbs, aerobact</i>	-	<i>NDM-1</i>	<i>qnrS, acc(6')-Ib-cr</i>
Kp33	Pus	<i>magA, rmpA, terW, silS, iutA, rmpA2, kfuBC, wcaG, allS, entB, ytbs, aerobact</i>	-	<i>NDM-1</i>	-
Kp34	Blood	<i>magA, rmpA, terW, silS, iutA, rmpA2, kfuBC, wcaG, allS, entB, ytbs, aerobact</i>	-	<i>KPC-2</i>	-
Kp35	Sputum	<i>magA, rmpA, terW, silS, iutA, rmpA2, kfuBC, wcaG, allS, kpn, entB, ytbs, aerobact</i>	<i>armA</i>	<i>NDM-1</i>	<i>TEM-1, acc(6')-Ib-cr</i>
T-KP35	-	-	-	<i>NDM-1</i>	-
Kp36	Blood	<i>rmpA, terW, silS, iutA, rmpA2, kpn, entB, ytbs</i>	<i>armA/rmtB</i>	<i>KPC-2</i>	<i>SHV-1, TEM-1, CTX-M-14, qnrS, acc(6')-Ib-cr</i>
T-KP36	-	-	<i>rmtB</i>	<i>KPC-2</i>	<i>TEM-1, acc(6')-Ib-cr</i>
Kp37	Blood	<i>terW, iutA, rmpA2, kpn, entB, ytbs, repA</i>	<i>armA/rmtB</i>	<i>KPC-2</i>	<i>SHV-1, TEM-1, CTX-M-14, qnrB</i>
T-KP37	-	-	-	-	-
Kp38	Sputum	<i>rmpA, terW, silS, iutA, rmpA2, kpn, entB, repA, aerobact</i>	<i>rmtB</i>	<i>NDM-1/KPC-2</i>	<i>TEM-1, CTX-M-14, qnrS, acc(6')-Ib-cr</i>
T-KP38	-	-	-	-	-
Kp39	Balf	<i>rmpA, terW, silS, iutA, rmpA2, kpn, entB, aerobact</i>	<i>rmtB</i>	<i>NDM-1</i>	<i>TEM-1, CTX-M-14, qnrS, acc(6')-Ib-cr</i>
T-KP39	-	-	-	-	-
J53	-	-	-	-	-

Figures




Figure 1

PFGE and MLST analysis of CR-hvKP isolates, the PFGE patterns have been organized according to a dendrogram of 39 CR-hvKP isolates based on MLST analysis.




Figure 2
S1-PFGE and Southern hybridisation of a portion of CR-hvKP strains in this study. A total of 39 nonduplicate CR-hvKP clinical isolates were collected from the First Affiliated Hospital of Nanchang University in the southeastern region of China. We select *K. pneumoniae* strains carrying the pLVPK-like virulence plasmid as hvKP strains by S1-PFGE and Southern hybridisation. The marker gene of the virulence plasmid *mpa2* was hybridised to confirm the presence of the pLVPK-like virulence plasmid.